Does Monjaro aggravate asthma
Checking Date & Time
Reading File
Finding Sources
Searching PubMed
tirzepatide AND asthma
Reading File
Reading Article
Reading Article
Finding Sources
Searching the Web
tirzepatide Mounjaro asthma exacerbations effect 2025 2026
Searching the Web
tirzepatide increased asthma risk CHEST 2025 GLP-1 RCT review
Searching the Web
tirzepatide FAERS adverse events asthma respiratory
I now have a well-rounded picture. Here is a comprehensive answer:
Does Mounjaro (Tirzepatide) Aggravate Asthma?
Short answer: No — the evidence leans toward benefit, but the picture is nuanced and agent-specific.
What is Mounjaro?
Mounjaro (tirzepatide) is a dual GLP-1 / GIP receptor agonist approved for type 2 diabetes and chronic weight management. It is not a bronchodilator or anti-inflammatory inhaler — it works primarily on appetite and glucose regulation. — Harrison's Principles of Internal Medicine 22E
Does it worsen asthma? Evidence says the opposite.
1. Fewer exacerbations in obese adults (2026, Clinical & Experimental Allergy)
A 2026 study (PMID 41708478, Mehta et al.) found that tirzepatide was associated with fewer asthma exacerbations in adults with obesity. This aligns with the well-established link between obesity and worse asthma — weight loss itself reduces mechanical load on the lungs and lowers systemic inflammation.
2. Anti-inflammatory mechanism in animal models (2025, Molecular Biology Reports)
A 2025 mouse study (PMID 41389087, Sun et al.) showed tirzepatide improved neutrophilic airway inflammation in obese asthmatic mice by downregulating Th17 cell differentiation — suggesting a direct anti-inflammatory airway effect beyond just weight loss.
3. Mater Research clinical trial (Feb 2026)
Mater Research (Australia) launched a clinical trial specifically studying Mounjaro in asthma patients, citing evidence that GLP-1 agonists may modulate airway inflammation and that weight loss from the drug may improve breathing mechanics.
The one signal of concern — CHEST 2025
A review presented at CHEST 2025 (Kulsum et al.) analyzed multiple RCTs and found a nuanced result:
- Semaglutide (Ozempic/Wegovy) → decreased asthma risk
- Tirzepatide and albiglutide → associated with increased asthma risk in some RCT analyses
This contradicts the assumption that all GLP-1 agents behave identically for asthma. The GIP receptor component in tirzepatide (which is absent in semaglutide) may have a different effect on airway biology — though data on GIP's role in airway inflammation is still limited. The CHEST finding has not yet been published as a full peer-reviewed paper and is currently a conference abstract.
Known respiratory adverse effects from FAERS (real-world data)
Real-world FAERS data (2022–2025) show tirzepatide's most common adverse events are gastrointestinal (nausea, diarrhea, vomiting). Respiratory events are not among the top reported signals, and asthma-specific worsening has not emerged as a safety flag in regulatory post-marketing surveillance.
Official prescribing information
The Mounjaro US prescribing information (Eli Lilly) does not list asthma exacerbation or bronchospasm as a known adverse effect. Key contraindications are: personal/family history of medullary thyroid cancer or MEN2.
Bottom Line
| Scenario | Evidence |
|---|---|
| Asthma in obese patients | Tirzepatide likely improves control via weight loss + reduced inflammation |
| Direct airway aggravation | Not established as a safety concern in regulatory data |
| vs. semaglutide for asthma | Semaglutide has stronger evidence for asthma benefit; tirzepatide data more mixed |
| Ongoing uncertainty | The GIP receptor's role in airway disease is still being studied |
For a patient with both asthma and obesity/diabetes, tirzepatide is not contraindicated because of asthma, but if asthma is a primary concern, discussing semaglutide as an alternative with the prescriber is reasonable given the CHEST 2025 signals. Any change in asthma control after starting Mounjaro should be reported to the treating clinician.
Sources: Harrison's Principles of Internal Medicine 22E | PMID 41708478 | PMID 41389087 | CHEST 2025 via Pharmacy Times | Mater Research Mounjaro Asthma Trial
This is a shared conversation. Sign in to Orris to start your own chat.